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 Antimicrobial resistance is a serious issue that is making it more difficult for doctors 
across the globe to treat patients suffering from microbial infections. Antimicrobial resistance 
refers to when microorganisms alter themselves in ways that make the medications used to cure 
the infections caused by said microorganisms ineffective. For the purpose of this paper, however, 
the focus is going to be on antibiotic resistance. Antibiotic resistance is a subset of antimicrobial 
resistance that allows specifically bacteria to develop the ability to overcome the drugs designed 
to inhibit and kill the bacteria themselves. Infections caused by antibiotic-resistant bacteria are 
often difficult or impossible to treat with medicine.  
The data and research included in this paper are aimed to better inform the public on the 
significance of antibiotic resistance. Excluding the obvious medical impact, antibiotic resistance 
also has a largescale impact on the economy. In addition, the data in this paper is also aimed to 
better inform the public about actions that contribute towards antibiotic resistance, as well as 
propose potential alternatives to just antibiotic medicine in terms of dealing with bacterial 
infections in order to help mitigate the spread of antibiotic resistance. If this could be 
accomplished, the ability of bacteria to persist and linger despite treatments would potentially 





 According to the Centers for Disease Control and Prevention (CDC), antibiotic resistance 
is one of the world’s most urgent health care problems 1. This is due to the fact that antibiotic 
resistance affects not only people at every stage of life, but also various industries such as 
healthcare, veterinary, and agriculture. In order to better understand just how serious of an issue 
antibiotic resistance is, it is important to first look at the history of antibiotics. Antibiotics were 
first discovered in 1928, when the Scottish physician Alexander Fleming discovered a certain 
mold that inhibited the growth of a Staphylococcal bacterium. He named the active substance 
from this mold culture “Penicillin”, which would eventually become the first commercialized 
antibiotic. 
 Since the discovery of Penicillin, 150 other antibiotics have been discovered 1. The 
discovery of antibiotics essentially changed the way that physicians were able to care for patients 
with bacterial infections. Physicians were able to shift away from diagnosing patients without 
having any means of healing, to being able to plan out treatments after diagnosis in order to 
actually save the lives of their patients. However, the emergence of resistance has closely 
followed the discovery of new antibiotics.  
After Penicillin was discovered in 1928, for example, it was approved for public use in 
1941. However, a Penicillin-resistant Staphylococcus aureus strain was identified as early as 
1942. Strains of Streptococcus pneumoniae were identified as Penicillin-resistant twenty-five 
years after that in 1967 and strains of Neisseria gonorrhoeae were identified as having 
Penicillin-resistance in 1976. Methicillin is an antibiotic that was approved for use in 1960 and a 
Methicillin-resistant strain of Staphylococcus aureus was already identified later that year. 
Azithromycin, on the other hand, was an antibiotic that did not have a resistant strain identified 
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for over thirty years. Approved for use in 1980, Azithromycin had a resistant strain of Neisseria 
gonorrhoeae identified in 2011. Even though it has only been roughly eighty years since the first 
antibiotic was approved for public use, we are already at the point where bacteria are evolving 
and developing resistance to antibiotics faster than scientists are developing and producing new 
antibiotics. Table 1 below, provided by the CDC, depicts the previously stated antibiotics and 
more, as well as the strains of antibiotic-resistant bacteria that followed them 1. 
Table 1: Antibiotics and their Correlating Resistant Bacterial Strains 1
 
As seen in the table above, Neisseria gonorrhoeae developed resistance to Penicillin in 
1976. Neisseria gonorrhoeae is a gram-negative, diplococcus bacterium that causes the well 
known sexually transmitted disease, gonorrhea. Figure 1 below is based off data collected from 
the CDC and depicts a timeline that shows how different antibiotics were used to treat gonorrhea 
and then subsequently outdated due to the development of resistance to said antibiotics 2. In 
Figure 1, Cefixime and Ceftriaxone are two forms of the antibiotic Cephalosporin. Cefixime is 
an oral form of Cephalosporin, while Ceftriaxone is an injectable form of Cephalosporin. From 
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the 1940s-2012, five different antibiotics were rendered ineffective against Neisseria 
gonorrhoeae. 
Figure 1: Timeline of Gonorrhea Developing Resistance to Various Antibiotics 2 
 
 Antibiotic-resistant bacteria such as these cause non-hospital-acquired infections in 
almost three million people every year, over 35,000 of whom die each year 1. They are also the 
cause of nearly two million hospital-acquired infections in the United States every year 3. 99,000 
of Americans end up dying from the infections. Antibiotic-resistant infections also cause the 
American health care system anywhere from $21 billion to $34 billion every single year. In 
addition, these types of infections cause hospital patients in America to stay an upward of eight 
million additional days every year.  
 In the agricultural industry, antibiotics are typically fed to food producing animals at 
doses lower than those prescribed to treat diseases. This approach increases the feed conversion 
efficiency, which in turn increases performance in those food producing animals 4. This 
prophylactic antibiotic treatment also contributes to a decrease in subclinical disease in these 
animals. As seen in the other industries, however, the short generation times of bacteria coupled 
with their ability to swap genetic material has led to antibiotic resistance developing in many of 
these animal-infecting bacteria.  
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One antibiotic, however, that has maintained its efficacy against a particular animal-
infecting bacterium is penicillin. Penicillin is just as effective against Streptococcus agalactia 
despite being used against it for over forty years 4. This differs vastly from the human bacteria 
that penicillin is used against. As seen in Table 1 above, three different bacterial strains had 
developed resistance against penicillin merely thirty-five years after penicillin had been 
approved for public use. This scenario of penicillin still being effective against Streptococcus 
agalactia is in the minority, sadly. Due to an overuse of antibiotics in the agriculture industry, 
antibiotic resistance has run rampant throughout animals that are processed for food. This is 
largely due to the ability of antibiotics to be used for growth promotion. Though regarded by the 
World Health Organization as inappropriate 5, medically important antibiotics are used 
extensively to increase animal growth rates. The resistance that this overuse of antibiotics causes 
affects not only the animals, but humans as well. The antibiotic resistance bacteria can be passed 
from the animals to the humans via  contaminated food. Even if the bacteria from the animals do 
not cause disease in humans, they can still pass along their genetic material that codes for 
resistance to other bacteria in the human body that do cause disease.  
 Misuse and overuse of antibiotics are major causes of this antibiotic resistance pandemic 
that is affecting these facets of everyday life. Typical misuse of antibiotics is seen when an 
individual is prescribed an antibiotic to take for a certain period of time but stops taking it before 
that time limit is reached because he/she feels better. This creates a phenomenon known as 
phenotypic persistence 6. During phenotypic persistence, the bacterial cells enter a period of 
inactivity where they are not replicating or expressing their pathogenicity. However, they are not 
completely killed off by the amount of antibiotic administered by that point. This is because 
enough of the antibiotic has been taken to inhibit the effects of the bacteria, but not enough has 
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been taken to induce bacterial cell death. So once the stressor, the uptake of antibiotics in this 
case, is removed, the Persister cells that are still alive begin to replicate again and resume their 
pathogenic effects. These Persister cells will now be able to survive the effects of the antibiotics 
that were previously used to inhibit them. This is why when someone does not finish taking their 
antibiotic completely and the bacterial infection returns, the antibiotic does not work as well as it 
did before. 
 As seen in the agriculture industry, antibiotic overuse is another major cause of antibiotic 
resistance, and this is also commonly seen with humans as well. Strep throat, for example, is a 
bacterial infection caused by Streptococcus. Most sore throats, however, are caused by viruses. 
Often times when people have sore throats, however, they will go to their health provider in 
order to be prescribed an antibiotic. When people take antibiotics while having no need for them, 
other non-pathogenic bacteria in the body are exposed to the antibiotic. When this happens, the 
non-pathogenic bacteria are able to develop resistant genes that they are then able to pass to other 
harmful bacteria when they enter the body. 
 Studies have been done in which antibiotic use in food animals was decreased and the 
effect this had on frequency of antibiotic resistance bacteria was measured. In a particular study 
that was performed in Japan in 2013 5, third-generation cephalosporins were removed from use. 
Before they were withdrawn, the prevalence of cephalosporin-resistant E. coli was measured to 
be 16.4%. After the withdrawal, the prevalence of cephalosporin-resistant E. coli was measured 
to be 4.6%. This study showed similar results as the other studies that were done previously. The 
data from these studies shows that limiting exposure of animals/humans to antibiotics lowers the 
prevalence of antibiotic-resistant bacteria in those animals/humans. This relates back to overuse 
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of antibiotics. If the overuse of antibiotics was reduced, then the frequency of antibiotic 
resistance could be lowered as well. 
 The misuse and overuse of antibiotics have contributed to the dramatic rise of antibiotic 
resistance, especially in recent years. Some examples of this rise in resistance can be seen in 
Figure 2 below 7. Figure 2 depicts a graph that shows the increasing prevalence of three different 
antibiotic-resistant bacterial strains over a twenty-year period from 1981-2001. The three strains 
depicted are Methicillin-Resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant 
Enterococcus (VRE), and Fluoroquinolone-Resistant Pseudomonas Aeruginosa (FQRP). Though 
it important to note that MRSA is no longer just resistant to methicillin. It is in fact resistant to 
several of the most common antibiotics in use, including amoxicillin, penicillin, and 
cephalosporins. 





Mechanisms of Antibiotic Resistance 
Mechanism 1: Beta-lactamase 
 Understanding the history and rise of antibiotic resistance is important for working 
towards reducing the spread of this antibiotic-resistance pandemic. However, understanding the 
various mechanisms bacteria utilize to develop resistance to antibiotics is important as well. One 
such mechanism that some bacteria utilize is beta-lactamase. Beta-lactamase enzymes are one of 
the most common causes of bacterial resistance to beta-lactam antibiotics. Beta-lactam 
antibiotics, which get their name from a beta-lactam ring present in their structure, are a very 
common kind of antibiotic that are primarily used to treat infections from gram-negative 
bacteria. The antibiotics do this by binding to and inhibiting the penicillin-binding proteins in 
these gram-negative bacteria 8. Doing this interferes with the gram-negative bacteria’s ability to 
synthesize their single peptidoglycan layer cell walls. Some common examples of beta-lactam 
antibiotics are penicillin, amoxicillin (basically all penicillin derivatives), cephalosporins, 
monobactams, carbapenems and carbacephems.  
Beta-lactamase enzymes covalently bind to the carbonyl group present in a beta-lactam 
antibiotic. This allows the enzymes to hydrolyze the amide bond in the beta-lactam ring that is 
present in the structure of said beta-lactam antibiotic. With this beta-lactam ring broken open, the 
molecule’s antibacterial properties are essentially deactivated 9. Figure 3 below depicts a graph 
that shows the rise of beta-lactamase enzymes in bacteria over a forty-year period from 1970-
2010 10. As seen in the graph, beginning at around the year 1990, the rate of discovery of unique 
beta-lactamase enzymes has increased exponentially. This is a serious issue because if bacteria 
keep expressing more and more beta-lactamase enzymes, soon a lot of the most widely used 
antibiotics will be rendered useless. 
10 
 
Figure 3: Beta-Lactamase Enzymes Discovered During the Age of Antibiotics 10 
 
Mechanism 2: Biofilms 
 Biofilms are another mechanism for antibiotic resistance in bacteria. They are thin, slimy 
films of bacteria that typically adhere to each other and whatever surface they are on in a moist 
environment. The films consist of DNA, proteins, and polysaccharides. These films of bacterial 
cells become embedded in an extracellular matrix that protects the bacteria from harmful 
external substances such as antibiotics. Biofilms are commonly seen in hospitals, where they 
grow on medical devices such as catheters, heart valves, and pacemakers. This can cause 
complications in those devices and are a big reason why antibiotic-resistant hospital acquired 
infections are such a big issue.  
 Tables 2 and 3 below from Gong et al. depict data from an article discussing antibiotic 
resistance and biofilm formation of Salmonella pullorum isolates from eastern China over a 
forty-eight-year time span from 1962-2010 11. Table 2 depicts data from the article in which it 
shows the number of Salmonella Pullorum isolates from their collected samples that are resistant 
to various antibiotics every few years. Taking a look at the first row, from 1962-1968, there were 
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2 isolates that were resistant to ampicillin. This then increased to 16, and then 19, and so on. The 
general trend is that as the years progress, the number of resistant isolates increase across the 
board for pretty much every antibiotic used. However, it is important to note that this does not 
always occur. I have highlighted in purple those few instances where this does not occur. The 
trend with those instances is that after a brief lull, the number of resistant isolates begins 
increasing again. 














Ampicillin 2 16 19 39 40 116 
Carbenicillin 3 6 11 28 38 86 
Cefamandole 6 27 32 29 63 157 
Cefotaxime 0 0 0 0 8 8 
Chloramphenicol 0 0 0 6 8 14 
Ciprofloxacin 0 0 0 0 15 15 
Gentamicin 0 0 2 4 12 18 
Kanamycin 0 0 1 2 10 13 
Nalidixic acid 0 0 0 3 61 64 
Nitrofurantoin 2 19 24 24 20 89 
Spectinomycin 0 4 10 13 18 45 
Streptomycin 5 26 49 53 75 208 
Sulfamethoxazole 10 66 46 25 31 178 
Tetracycline 6 35 53 49 55 198 
Trimethoprim 3 68 70 52 86 279 
Trimethoprim/sulfamethoxazole 0 20 33 35 79 167 
 
 Table 3 below also correlates with the article discussing antibiotic resistance and biofilm 
formation of Salmonella pullorum isolates from eastern China 11. Table 3 shows the number of 
Salmonella pullorum isolates collected in each time span along with the number of said isolates 
that had formed biofilms. So, to clarify, from 1962-1968 they collected 32 isolates, and of those 
32 isolates, 16 formed biofilms. The percentage column highlighted in yellow is something that 
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was not included in the original data. I added that column to make it easier to visualize the trend 
quantified in the data. As you can see, the percentage of isolates that form biofilms have 
increased over the years. This directly correlates with the increase in antibiotic resistance 
expressed by the Salmonella pullorum isolates over the same time span as seen in the first table, 
indicating that increasing biofilm formation has also contributed to increasing antimicrobial 
resistance. 
Table 3: Biofilm Formation of Salmonella pullorum Isolates 11 
Years Number of isolates Number of biofilm-positive isolates Percentage 
1962 to 1968 32 16 50 
1970 to 1979 82 47 57.32 
1980 to 1987 75 46 61.33 
1990 to 1999 56 40 71.43 
2000 to 2010 92 71 77.17 
Total 337 220   
 
Mechanism 3: Active Efflux  
Another mechanism that bacteria utilize in order to develop resistance to antibiotics is active 
efflux. Efflux pumps are systems in microorganisms that pump solutes out of the cells. This in 
turn allows the microorganisms to regulate their internal environment by removing substances 
that are toxic to the microorganisms 12. Bacteria can utilize efflux pumps to export the antibiotics 
out of the cytoplasm and into extracellular media. Efflux Pumps are active transporters that are 
located in the cytoplasmic membrane. Some pumps are primary active transporters, meaning 
they use ATP hydrolysis as an energy source. Other pumps are secondary active transporters, 
which means that the transport is coupled with an electrochemical potential difference. This 
difference is created by pumping either hydrogen or sodium ions into the cell. 
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Figure 4 below depicts the general mechanism behind active efflux 13. When antibiotics enter 
the cell, they bind to the inner membrane protein that is a portion of the efflux pump. This then 
initiates a biochemical cascade which signals the periplasmic membrane protein and the outer 
membrane protein (which are also parts of the efflux pump), making them open and eject the 
antibiotics. Keep in mind this is a very generalized way of showing active efflux; there are 
actually five different families of efflux transporters that work in slightly different ways and for 
different kinds of bacteria. At the end of the day, however, they achieve the same result. The five 
families of efflux pump transporters are the major facilitator superfamily, the ATP-binding 
cassette superfamily (which is the only primary active transporter family), the small multidrug 
resistance family, the resistance-nodulation-cell division superfamily, and the multi antimicrobial 
extrusion protein family. 





Mechanism 4: Vertical and Horizontal Gene Transfer 
As mentioned in the introduction, the misuse and overuse of antibiotics are a major cause 
of antibiotic resistance. To reiterate, misuse occurs when people stop taking their antibiotics once 
they start feeling better, even if they still have a few days of treatment left. Since specific 
antibiotics are prescribed for specific bacterial infections, there are set times for a patient to take 
said antibiotic to completely eradicate the bacteria causing the infection. When patients do not 
take the antibiotics for the full length of time, some of the bacteria are able to survive and 
reproduce. This time however, the parent bacteria adapt to selective pressure from the antibiotics 
and exhibit antibacterial resistant properties, which they pass on to the offspring. This way, if the 
same antibiotic is used again, it either will not be as effective or will not be effective at all. This 
transfer of genetic material from parent to offspring is the mechanism known as Vertical Gene 
Transfer, which is outlined in part A of Figure 5 below 14. Vertical Gene Transfer is a major 
cause of the spreading of antibiotic resistance. 
As previously stated, overuse of antibiotics is often seen people are over-prescribed 
antibiotics for non-bacterial infections. For example, while taking antibiotics for a viral infection 
will not have an effect on that viral infection, it can be detrimental later in life. If there were non-
harmful bacteria present in the body that the antibiotic attacked and some survived, those 
bacteria could reproduce and make more strains that are resistant to the antibiotic. When a 
harmful bacteria does eventually enter the body, these non-harmful bacteria could transfer 
resistance to the harmful bacteria. This transfer of genetic material is the mechanism known as 
Horizontal Gene Transfer, which is outlined in part B of Figure 5 below 14. Horizontal Gene 
Transfer is also a major cause of the spreading of antibiotic resistance. 
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In layman’s terms, horizontal gene transfer is the movement of genetic material between 
organisms by means that are not reproduction. As noted in part B of the figure below, there are 
three primary mechanisms that mediate horizontal gene transfer. Transformation is the uptake of 
free DNA. Short fragments of naked DNA are taken up by naturally transformable bacteria. 
Transduction is phage-mediated transfer. The DNA is taken up from one bacterium via a 
bacteriophage and then inserted into another bacterium. Conjugation is plasmid-mediated 
transfer. The donor bacterium has a DNA sequence known as the fertility factor that allows the 
donor bacterium to produce a pilus, which is a tubelike structure. The donor bacterium will 
contact the recipient bacterium via the pilus and transfer the genetic material, usually in the form 
of a plasmid. 





Suggested Plans of Action 
General Strategies 
 Antibiotic resistance is a serious issue that can be lessened with a few safer practices. 
One simple practice is better hand washing. Since hands are used to touch numerous items and 
people every day, they make great vectors for spreading antibiotic-resistant bacteria. According 
to Harvard Medical, washing hands for fifteen seconds removes around 90% of bacteria. An 
additional fifteen seconds increases this percentage to 99.9% 15. It is important to note that these 
numbers are measured in logarithmic reduction. In order to better understand these percentages, 
take a look at the following hypothetical situation. Say after washing hands for fifteen seconds, 
the hands of an individual had a bacterial count of 100,000; an additional fifteen seconds would 
lower that count to 1000. However, it is important to keep in mind not to overdo handwashing. 
Too much handwashing can lead to dry skin with cuts, which makes a great reservoir for 
bacteria.  
 As per the CDC, immunizations and better food preparation are also effective strategies 
in lowering the spread of antibiotic resistance 16. Many of the bacterial infections people acquire 
are through the consumption of foods that are not properly washed or prepared. In addition, 
using antibiotics as directed is a major strategy in dealing with antibiotic resistance. As described 
in the mechanisms section above, taking antibiotics for the full length of time greatly reduces the 
risk of Vertical Gene Transfer. According to the CDC, improving antibiotic prescribing is 
perhaps the most important course of action needed in reducing the spread of antibiotic 
resistance 16. Around half of the antibiotics prescribed for use in humans and in animals are 
unnecessary. Lowering this number would dramatically reduce the risk of Horizontal and 




 Since beta-lactam antibiotics comprise approximately 60% of the world’s antibiotic 
usage, it is important to look at methods to help counter beta-lactamase producing bacteria. One 
such method is administering beta-lactam antibiotics with beta-lactamase inhibitors. Three such 
inhibitors that have been in use are clavulanic acid, sulbactam, and tazobactam. These beta-
lactamase inhibitors develop irreversible “suicide inhibitors” that are able to inactivate the beta-
lactamase forever through secondary chemical reactions in the enzyme active site 17. These 
inhibitors, however, are not broad spectrum. They only work on a few beta-lactamase bacteria. In 
addition, there has been a rise in prevalence of a beta-lactamase known as AmpC in recent years. 
AmpC beta-lactamases are able to mediate resistance to the beta-lactamase inhibitor-beta-lactam 
antibiotic combinations that are in use today due to mutations of amino acids in the active site.  
 Due to this rise of AmpC beta-lactamase mediated resistance, as well as the narrower 
focus of the current beta-lactamase inhibitors, there is an increasing need for new, synthetic 
broad-spectrum beta-lactamase inhibitors. In order to successfully prevent beta-lactamase 
mediated resistance, it is important to use substances that are designed to bind at the active site. 
The “suicide inhibitors” mentioned above depict one way to accomplish this. Another way to 
accomplish this task is by creating substrates that can reversibly and/or irreversibly bind the beta-
lactamase enzyme with high affinity while forming unfavorable steric interactions as acyl-
enzymes 17. Carbapenems and monobactams have been found to be good examples of this 
method that form acyl-enzymes and take on catalytically ineffectual conformations, which leads 
to effective inhibition of AmpC beta-lactamases. However, more experimentation still needs to 




Laser Treatment for Biofilms 
 Due to the growing pervasiveness of biofilm-related multi-drug resistant bacteria, 
especially in hospitals, it is especially important to look at non-conventional ways of dealing 
with biofilms. One common proposition in recent years has been to utilize laser treatments to 
deal with these multi-drug resistant bacterial biofilms. Kirui et al. analyzes the efficacy of gold 
nanoparticle-targeted pulsed laser therapy against biofilms from methicillin-resistant 
Staphylococcus aureus and multi-drug resistant Pseudomonas aeruginosa in vitro 19. They first 
tested just the ability of gold nanoparticle-targeted pulsed laser therapy to disperse biofilms. 
Then they combined gold nanoparticle-targeted pulsed laser therapy with antibiotics to test 
whether or not the biofilms of the bacteria were more susceptible to the antibiotics. 
 Gold nanoparticle-targeted pulsed laser therapy first consisted of attaching antibodies to 
gold nanoparticles to induce site-specific delivery. If this method were to be used in vivo, 
damage to healthy surrounding tissue would be minimized due to this site-specific delivery. 
Biofilms were treated with these antibody-conjugated gold nanoparticles and then immediately 
treated with a nanosecond-pulsed laser irradiation at 532 nanometers. This is all depicted in 
Figure 6 below. This strategy, when compared to the control, dispersed 96-99% of the biofilms 
while killing around 90-98% of the biofilm-associated bacteria. While these numbers should be 
improved upon, they are a very promising start. 
 This gold nanoparticle-targeted pulsed laser therapy was then used in conjunction with 
the antibiotics gentamicin and amikacin. These combinations caused a 4-log reduction in biofilm 
viability for methicillin-resistant Staphylococcus aureus (99.99% reduction) and a 5-log 
reduction in biofilm viability for multi-drug resistant Pseudomonas aeruginosa (99.999% 
19 
 
reduction). The use of gold nanoparticle-targeted laser therapy or antibiotics individually only 
reduced biofilm viability by approximately 1-log (90%). 
Figure 6: Gold Nanoparticle-targeted Pulsed Laser Therapy 19 
 
 
Active Efflux Inhibitors 
 Due to the fact that active efflux is such an effective mediator of antibiotic resistance, it is 
important to look at ways to bypass the abilities of efflux pumps. This can be done in a number 
of ways, including interfering with genetic regulation in order to downregulate the expression of 
efflux pump genes, reshaping antibiotics so that they are no longer identified as substrates, 
blocking the actual assembly of working efflux pumps, avoiding substrate binding by blocking 
the pump, and taking care of the energy mechanism behind powering the pumps 20. A review by 
Sharma et al. examines these last two methods to inhibit efflux pumps by using chemical units 
known as efflux pump inhibitors. Efflux pump inhibitors (EPI) have been analyzed for the past 
several years as a potential means of resurgence for older antibiotics that are no longer effective 
due to the resistance caused by efflux pumps. It is important to note that in order to be effective 
and lasting, the EPI molecules can not be antibacterial. This is because an antibacterial would 
eventually lead to resistant mutants of the target 20. 
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 One mechanism of efflux pump inhibition Sharma et al. looked at was the binding of 
EPIs to efflux pumps. This binding decreased the ability of efflux pumps to bind to substrate-
identified antibiotics and pump them out of the cell 20. The binding of EPI to efflux pump can 
come in two different types. One is competitive binding, where the EPI competes with the 
substrate antibiotics for the same binding site. The other is non-competitive binding, where the 
binding of the EPI to the efflux pump lowers the attraction of the efflux pump towards substrate 
antibiotics. There are several molecules that have been found that exhibit these kinds of binding 
to be used as EPIs, however they are still in the experimental stage due to the expression of 
strong antibacterial properties and a lack of evidence regarding mechanisms of action 20. 
 Another mechanism of efflux pump inhibition that Sharma et al. reviewed was energy 
dissipation. Efflux pumps depend on cellular energy, so the dissociation of this energy looks to 
be a promising mechanism for efflux pump inhibition. The proton gradient and the ATPase that 
supply energy to efflux pumps have been targeted by various potential EPIs over the years. This 
seems to be an advantageous approach as the inhibitor does not require contact with the efflux 
pump, which lowers the chances of resistant mutations (but does not eradicate) 20. Targeting the 
proton gradient is also a universal proposal for inhibiting efflux pumps as all efflux pumps 
depend on proton gradients. This paper analyzes a few proposed EPIs that are in the work that 
target energy dissipation. The most well-known, Carbonyl cyanide-m-chlorophenylhydrazone, is 
very effective at disrupting proton motive force and making bacterial cells metabolically 
inactive. However, it has not been approved for pharmaceutical use due to the fact that it exhibits 
cellular toxicity towards mammalian cells. Synthetic EPI IITR08027 is also a promising EPI that 
was analyzed that has very low toxicity toward mammalian cells, which is why it currently being 




 Antibiotic resistance is a widespread issue that impacts various aspects of life across the 
globe. It is becoming a more severe issue each and every day. If no serious actions are taken to 
help combat this rise of antibiotic-resistant bacteria, scientists propose that the world may soon 
face an era similar to pre-antibiotic times. Medically, these were darker times when the simplest 
bacterial infection could kill a person. By understanding the history of and contributions towards 
the rise of antibiotic resistance, people can move forward and implement safer practices to help 
decelerate and potentially reverse this rise. While scientists focus on combating the mechanisms 
of antibiotic resistance in the labs, the public can focus on lowering the misuse and overuse of 
antibiotics in order to do their share of lowering the spread of antibiotic resistance. Unless a 
greater focus is placed on these kinds of actions, the global pandemic known as antibiotic 
resistance may change bacterial infections as we know them, and not in a good way. 
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